JP2005513024A - グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療 - Google Patents

グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療 Download PDF

Info

Publication number
JP2005513024A
JP2005513024A JP2003545321A JP2003545321A JP2005513024A JP 2005513024 A JP2005513024 A JP 2005513024A JP 2003545321 A JP2003545321 A JP 2003545321A JP 2003545321 A JP2003545321 A JP 2003545321A JP 2005513024 A JP2005513024 A JP 2005513024A
Authority
JP
Japan
Prior art keywords
day
dose
administering
antagonist
cortisol levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003545321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513024A5 (https=
Inventor
ペーテル，ベルナルダス・ウイユナンド・マテイス、マリー
セネフ，コーネリス
Original Assignee
アクゾ・ノベル・エヌ・ベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクゾ・ノベル・エヌ・ベー filed Critical アクゾ・ノベル・エヌ・ベー
Publication of JP2005513024A publication Critical patent/JP2005513024A/ja
Publication of JP2005513024A5 publication Critical patent/JP2005513024A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2003545321A 2001-11-23 2002-11-18 グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療 Withdrawn JP2005513024A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204518 2001-11-23
PCT/EP2002/012854 WO2003043640A2 (en) 2001-11-23 2002-11-18 Treatment of major depressive disorder using glucocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
JP2005513024A true JP2005513024A (ja) 2005-05-12
JP2005513024A5 JP2005513024A5 (https=) 2006-01-05

Family

ID=8181289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545321A Withdrawn JP2005513024A (ja) 2001-11-23 2002-11-18 グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療

Country Status (5)

Country Link
US (1) US8193172B2 (https=)
EP (1) EP1453495A2 (https=)
JP (1) JP2005513024A (https=)
AU (1) AU2002366217A1 (https=)
WO (1) WO2003043640A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
WO2007131041A2 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
AU2016226451B2 (en) 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
US10610534B2 (en) 2015-03-30 2020-04-07 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
JP6765443B2 (ja) 2016-01-19 2020-10-07 コーセプト セラピューティクス， インコーポレイテッド 異所性クッシング症候群の鑑別診断
US11702443B2 (en) * 2016-10-04 2023-07-18 Pop Test Oncology Llc Therapeutic agents and methods
US11040037B2 (en) * 2016-10-04 2021-06-22 Pop Test Oncology Llc Therapeutic agents and methods
WO2018236749A2 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09104696A (ja) * 1995-08-17 1997-04-22 Akzo Nobel Nv １１−（置換フェニル）−エストラ−４，９−ジエン誘導体
JP2001518509A (ja) * 1997-10-06 2001-10-16 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ グルココルチコイド関連機能不全に関連した精神病の処置のための方法。

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
EP0683172B1 (en) 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
AP1542A (en) 1999-04-30 2006-01-31 Pfizer Prod Inc Glucocorticoid receptor modulators.
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
DE60232956D1 (de) * 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09104696A (ja) * 1995-08-17 1997-04-22 Akzo Nobel Nv １１−（置換フェニル）−エストラ−４，９−ジエン誘導体
JP2001518509A (ja) * 1997-10-06 2001-10-16 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ グルココルチコイド関連機能不全に関連した精神病の処置のための方法。

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BACHMANN, C.G. ET AL., EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. Vol.10, Suppl.3, JPN6008063033, 2000, pages 271 - 272, ISSN: 0001202234 *

Also Published As

Publication number Publication date
WO2003043640A2 (en) 2003-05-30
WO2003043640A3 (en) 2004-03-04
US8193172B2 (en) 2012-06-05
AU2002366217A8 (en) 2003-06-10
US20050020480A1 (en) 2005-01-27
AU2002366217A1 (en) 2003-06-10
EP1453495A2 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
Nieman et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486
EP3263112B1 (en) Compositions and methods for suppressing endometrial proliferations
US20210128584A1 (en) Use of glucocorticoid receptor antagonists for the treatment of amyotrophic lateral sclerosis
KR20210153056A (ko) 인슐린 감수성 개선 방법
EP2576582B1 (en) Treatment of muscular dystrophy
JP2005513024A (ja) グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療
JP2000513704A (ja) 麻薬禁断症候群に対する抗ミネラロコルチコイド化合物の新規な用途
CA2504751A1 (en) Methods for treating gastroesophageal reflux disease
CA2459033C (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
JP4647909B2 (ja) 大うつ病性障害の治療における（１１β，１７β）−１１−（１，３−ベンゾジオキソール−５−イル）−１７−ヒドロキシ−１７−（１−プロピニル）エストラ−４，９−ジエン−３−オンの使用
JPH07278017A (ja) 麻薬又は麻薬混合物からの自然の又は早められた退薬症状と関連した徴候を予防し又は治療するための薬剤の製造への抗グルココルチコイド活性を有する化合物の使用及びそれらを含有する組成物
AU2002348996A1 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder
HK1087357B (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
Hallmayer Mifepristone treatment for psychotic depression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051021

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100901

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100924

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110525

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120220